Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Year: 2023
Type: article
Abstract: Objective: To retrospectively assess the biological response in cats with pancreatic carcinoma treated with toceranib phosphate. Animals: Twenty-six client-owned cats. Procedure: an emailed REDCap survey. For inclusion, cats were required to have a confirmed diagnosis of exocrine pancreatic carcinoma either by histopathology, cytology, or both; to have received treatment with toceranib phosphate; and to have adequate follow-up data for analysis. Results: = 8). The remaining 11 cats with gross disease did not respond to toceranib phosphate. In the cats with microscopic disease, response was mixed. The median survival time for all cats was 97 d (range: 1 to 1666 d). Conclusion: Toceranib phosphate was well-tolerated and provided modest clinical benefit to a subset of cats treated. Clinical relevance: Although feline exocrine pancreatic carcinoma continues to be a challenging disease to treat, toceranib phosphate appeared to provide potential clinical benefit.
Source: PubMed Central
Authors: Carlos Ortiz Rosario, Margaret L Musser, Lignan Yuan, Jonathan P Mochel, Jessica Talbott, Chad M Johannes, Erika P Berger
Institutions: Iowa State University, MSPCA-Angell
Language: English
Topic: Veterinary Oncology Research
Subfield: Small Animals
Field: Veterinary
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4389315610
